SCHEMBL5270380

SCHEMBL5270380

CCOc1cccc(-c2ccc(-c3coc4cc(O)c(Cl)cc4c3=O)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH2 P05091 12/20 0.59
▸ MAOA P21397 5/20 0.59
▸ MAOB P27338 5/20 0.59
▸ KLK7 P49862 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ MAPT P10636 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ PPARG P37231 2/20 0.48
▸ PPARD Q03181 1/20 0.48
▸ PPARA Q07869 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.45
▸ PTPN1 P18031 1/20 0.45
▸ RXRA P19793 1/20 0.45
▸ RXRB P28702 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5271894 0.83 PPARG (0.69) MAOAMAOBKLK7RAB9AMAPT
SCHEMBL5267794 0.82 ALDH2 (0.50) ALDH2MAOAMAOBMAPTPPARG
SCHEMBL4175173 0.80 ALDH1A1 (0.63) ALDH2MAOAMAOBKLK7RAB9A
SCHEMBL5269467 0.79 PPARG (0.46) ALDH2MAOAMAOBMAPTPPARG
SCHEMBL5267899 0.79 ALDH2 (0.46) ALDH2MAOAMAOBPPARGPPARD
SCHEMBL5266781 0.78 RAB9A (0.54) ALDH2MAOAMAOBKLK7RAB9A
SCHEMBL19236369 0.78 ALOX12 (0.62) ALDH2MAOAMAOBKLK7RAB9A
SCHEMBL678221 0.77 ALOX15 (0.78) ALDH2MAOAMAOBKLK7RAB9A
SCHEMBL5272367 0.77 PPARG (0.64) KLK7RAB9AMAPTPPARGPPARD
SCHEMBL14396312 0.77 ABCB1 (0.61) KLK7RAB9AMAPTPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 — — US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 — — EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P ALDH2 736/4885MAOA 4239/4885MAOB 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback